Across 10 randomized controlled trials enrolling 6,515 overweight or obese adults, tirzepatide — the dual GIP/GLP-1 receptor agonist — produced pooled odds ratios of 2.20 (95% CrI, 0.81–6.75) for atrial fibrillation and 2.16 (95% CrI, 0.90–5.87) for atrial arrhythmia, both crossing unity and statistically non-significant. However, the composite any-arrhythmia endpoint reached a credible interval excluding 1.0 — OR 1.84 (95% CrI, 1.04–3.90) — suggesting a real, if modest, pro-arrhythmic signal.
This finding arrives at a consequential moment. Tirzepatide has rapidly become a cornerstone of metabolic and cardiovascular medicine following the SURMOUNT and SURPASS trial families, and obesity itself is a major independent risk factor for atrial fibrillation — creating a confounding backdrop that makes signal detection genuinely difficult. The broader arrhythmia signal here may reflect autonomic modulation by GIP/GLP-1 dual agonism, sympathetic activation during rapid weight loss, or electrolyte shifts — mechanisms poorly characterized in current literature. Critically, the analysis pools only 6,515 participants, far underpowered to detect rare cardiac events reliably. The Bayesian hierarchical approach is appropriate for rare events but cannot substitute for dedicated cardiovascular safety surveillance. For clinicians prescribing tirzepatide, this is a cautionary rather than prohibitive signal — incremental in nature, but warranting prospective cardiac monitoring protocols in future large-scale trials like SURMOUNT-CVD.